Skip to main content

Table 1 Baseline demographics and disease characteristics (safety set)

From: Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD ‘real world’ study

 

LABA/LAMA FDC (N = 340)

Triple therapy (N = 784)

Sex, n (%)

  

 Male

172 (50.6)

477 (60.8)

 Female

168 (49.4)

307 (39.2)

Age (years), mean (SD)

69.9 (9.9)

68.8 (9.2)

Age groups, n (%)

  

  < 65 years

100 (29.4)

258 (32.9)

 65–75 years

129 (37.9)

312 (39.8)

  > 75 years

111 (32.6)

214 (27.3)

Body-mass index (kg/m2), mean (SD)

27.8 (5.8)

27.2 (5.5)

Duration since primary diagnosis (years), mean (SD)

6.7 (4.7)

8.0 (5.6)

Duration since primary diagnosis, n (%)

  

  ≤ 1 year

26 (7.6)

43 (5.5)

  > 1 year

305 (89.7)

707 (90.2)

Missing values

9 (2.6)

34 (4.3)

Symptoms of COPD*, n (%)

  

 None

0 (0.0)

0 (0.0)

 Exertional dyspnoea

314 (92.4)

747 (95.3)

 Dyspnoea at rest

90 (26.5)

194 (24.7)

 Chest tightness/chest pain

150 (44.1)

327 (41.7)

 Cough

291 (85.6)

653 (83.3)

 Wheezing or grunting

104 (30.6)

266 (33.9)

 Prolonged expiration

123 (36.2)

251 (32.0)

 Restricted exercise tolerance

265 (77.9)

653 (83.3)

 Missing values

4 (1.2)

7 (0.9)

FEV1 (litres), mean (SD)

1.7 (0.7)

1.5 (0.6)

FEV1 predicted, mean (SD)

66.9 (24.7)

57.7 (22.8)

Smoking status, n (%)

  

 Smoker

115 (33.8)

235 (30.0)

 Ex-smoker

168 (49.4)

435 (55.5)

 Non-smoker

57 (16.8)

114 (14.5)

Years smoking, mean (SD)

34.4 (10.1)

35.2 (11.8)

Pack-years, mean (SD)

35.2 (18.8)

36.1 (22.0)

  1. *More than one symptom possible per patient. Only smokers and ex-smokers. LABA long-acting β2-agonist, LAMA long-acting muscarinic antagonist, FDC fixed-dose combination, SD standard deviation; COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 s